Kindeva Drug Delivery announced today that it appointed David Stevens as its global chief commercial officer (CCO).
Stevens’ role includes spearheading the commercial, business development and R&D activities for Kindeva. He aims to ensure continued growth, expansion and innovation from the drug delivery device contract development and manufacturing organization (CDMO).
“David brings a breadth of industry experience and a depth of commercial expertise that is essential for driving Kindeva’s enhanced scope and scale,” said Kindeva CEO Milton Boyer. “His role is vital to our continued success as a premier CDMO and, in turn, the success of our partners bringing a broad range of drug delivery solutions to market.”
Stevens brings more than 20 years of experience in international and commercial operations. His experience spans the CDMO and contract research organization (CRO) sectors.
Before joining Kindeva, Stevens served as CEO of advanced therapy CDMO Arranta Bio (acquired by Recipharm last year). There, he built out two advanced biologics development and GMP manufacturing facilities. Prior to Arranta, he held multiple roles at MRI, leading the company’s drug product business. Past experience also includes roles at Aptuit, Inveresk and Charles River Laboratories.
“The Kindeva organization has a strong history of achievement, expertise, and the infrastructure to handle an extensive range of critical complex drug delivery challenges,” Stevens said. “I am excited to work with the incredible experts bringing many life-changing therapies and the highest-quality products to patients, and I am looking forward to leveraging my commercial, operational, and strategic background to enable continued success for our partners worldwide.”